Show simple item record

dc.contributor.advisorSánchez, José Ignacio
dc.contributor.authorCasiano Beltrán, Wilmar Gonzalo
dc.contributor.authorSuarez Cardona, David Andrés
dc.coverage.spatialHospital Militar Centralspa
dc.coverage.temporal2019/2021spa
dc.date.accessioned2021-08-04T19:47:30Z
dc.date.available2021-08-04T19:47:30Z
dc.date.issued2021-05-28
dc.identifier.urihttp://hdl.handle.net/10654/38444
dc.description.abstractEn la última década se han desarrollado una serie de estrategias encaminadas a reducir el sangrado intraoperatorio y evitar la necesidad de transfusión sanguínea en reemplazos articulares primarios de rodilla, utilizando medidas no farmacológicas como el uso de torniquete y farmacológicas en donde se destaca el uso de agentes antifibrinolíticos, especialmente el ácido tranexámico (ATX). Objetivo: Evaluar si en el reemplazo articular primario de rodilla el uso ácido tranexámico contribuyó a la disminución de pérdidas sanguíneas intraoperatorias y la necesidad de transfusión intra y postoperatoria en el hospital militar central entre enero del 2013 a febrero del 2020. Métodos: estudio observacional descriptivo corte transversal de expuestos y no expuestos, entre el primero de enero del 2013 al 29 de febrero del 2020 de pacientes con indicación de un reemplazo articular primario de rodilla Resultados: en la cuantificación de HB POP 24h que los pacientes que mantuvieron mayores cantidades de hemoglobina fueron en los que se utilizó el ATX asociado o no al uso del torniquete con un promedio mayor de 0.3gr de hemoglobina, además los pacientes en los que no se utilizó el ATX a pesar del uso de torniquete presentaron mayores pérdidas sanguíneas intraoperatorias promediando 32cc. Conclusiones: El hallazgo más importante de nuestro estudio es que en los pacientes en los que se utiliza el ATX tanto de manera IV como en combinación IV+TÓPICO muestran una disminución en las pérdidas sanguíneas intra y postoperatorias lo que influiría en la menor necesidad de requerimientos de transfusiones sanguíneas. Palabras claves: ácido tranexámico, transfusión sanguínea, reemplazo total primario de rodillaspa
dc.description.tableofcontentsTabla de contenido Resumen 4 Marco teórico 5 Planteamiento del problema 11 Justificación 12 Objetivos 13 General 13 Específicos 13 Metodología 14 Diseño de la investigación 14 Población y muestra 14 Criterios de selección de la muestra 15 Instrumentos, Recolección de la información 15 Variables 16 Control de calidad de los datos 19 Plan de análisis de la información: 19 Resultados esperados 20 Cronograma 21 Presupuesto 22 Gastos personales 23 Gastos en materiales 23 Consideraciones éticas 24 Resultados obtenidos 25 Conclusiones 32 Trayectoria y hoja de vida de los investigadores 33 Bibliografía 35spa
dc.format.mimetypeapplicaction/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleDescripción de los resultados del uso de ácido tranexámico en la disminución de pérdidas sanguíneas intraoperatorias y necesidad de transfusión sanguínea en reemplazo articular primario de rodilla en el Hospital Militar Centralspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa
dc.description.abstractenglishIn the last decade, a series of strategies have been developed aimed to reduce intraoperative bleeding and avoiding the need of blood transfusion in primary knee joint replacements, the use of non-pharmacological measures such as the use of tourniquet and pharmacological measures where the use of antifibrinolytic agents are highlighted especially the tranexamic acid (TXA). Objective: To assess whether in primary knee joint replacement the use of tranexamic acid contributed to the decrease in intraoperative blood losses and the need of intraoperative and postoperative transfusions in the Hospital Militar Central between January 2013 and February 2020. Methods: cross-sectional descriptive observational study of exposed and unexposed, between January 1, 2013 and February 29, 2020 of patients with the medial indication of a primary knee joint replacement Results: in the quantification of HB POP 24h, the patients who maintained higher amounts of hemoglobin were those in which the TXA was used associated or not with the use of the tourniquet with an average greater than 0.3gr of hemoglobin, moreover the patients in whom the tranexamic acid was not used despite the use of a tourniquet, they presented greater intraoperative blood losses, averaging 32cc. Conclusions: The most important finding of our study is that patients in whom TXA is used both IV and in combination IV + TOPIC show a decrease in intra and postoperative blood loss, which would influence the lower need for requirements of blood transfusions. Key words: tranexamic acid, blood transfusion, primary total knee replacementspa
dc.title.translatedDescription of tranexamic acid use for reduction of intraoperative blood losses and the need for blood transfusion in primary knee joint replacement at the Hospital Militar Centralspa
dc.subject.keywordstranexamic acidspa
dc.subject.keywordsBlood transfusionspa
dc.subject.keywordsPrimary total knee joint replacementspa
dc.publisher.programOrtopedia y Traumatologíaspa
dc.creator.degreenameEspecialista en Ortopedia y Traumatologíaspa
dc.subject.decsORTOPEDIAspa
dc.subject.decsTRAUMATOLOGIAspa
dc.subject.decsARTOPLASTIA DE REEMPLAZO DE RODILLAspa
dc.subject.decsTRANSFUSION SANGUINEAspa
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyFacultad de Medicinaspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.creativecommonsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.relation.references[1] M. Muñoz Gómez and J. A. Páramo Fernández, “Intravenous administration of tranexamic acid to decrease bleeding and transfusion in knee and hip prosthetic surgery: Is it safe and cost-effective?,” Med. Clin. (Barc)., vol. 141, no. 5, pp. 207–209, 2013.spa
dc.relation.references[2] M. Goldstein, C. Feldmann, H. Wulf, and T. Wiesmann, “Tranexamic acid prophylaxis in hip and knee joint replacement,” Dtsch. Arztebl. Int., vol. 114, no. 48, pp. 824–830, 2017.spa
dc.relation.references[3] “Bundesinstitut für Arzneimittel und Medizinprodukte: Trasylol® (Aprotinin): Umsetzung der Kommissionsentscheidung zum Ruhen der Zulassung. www.bfarm.de/SharedDocs/Risikoinformationen/ Pharmakovigilanz/DE/RI/2008/RI-aprotinin.html (last accessed on 22 June.”spa
dc.relation.references[4] “Draxler DF, Medcalf RL: The fibrinolytic system—more than fibri- nolysis? Transfus Med Rev 2015; 29: 102–9.”spa
dc.relation.references[5] “McCormack PL: Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72: 585–617.”spa
dc.relation.references[6] “Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM: Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93: 1577–85.”spa
dc.relation.references[7] “Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA: Tranexamic acid-associated seizures: causes and treatment. Ann Neurol 2016; 79: 18–26.”spa
dc.relation.references[8] “Koscielny J, Jambor C: Perioperativer Einsatz von Antifibrinolytika. Vascular Care 2008; 15: 32–51.”spa
dc.relation.references[9] “Later AFL, Sitniakowsky LS, van Hilten JA, et al.: Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg 2013; 145: 1611–6.”spa
dc.relation.references[10] “PFIZER PHARMA PFE GmbH: Fachinformation „Cyclocapron®“. Fa. Pfizer. www.pfizermed.de/fileadmin/produktdatenbank/pdf/ 008797_freigabe.pdf (last accessed on 21 February 2016.”spa
dc.relation.references[11] “Levrat A, Gros A, Rugeri L, et al.: Evaluation of rotation thrombelasto graphy for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792–7.”spa
dc.relation.references[12] “Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE: Tran examic acid in trauma: how should we use it? Trauma Acute Care Surg 2013; 74: 1575–87.”spa
dc.relation.references[13] “Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: A meta-analysis. Anaesth Intensive Care. 2003;31:529–37.”spa
dc.relation.references[14] “Cid J, Lozano MI. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: Results of a metaanalysis of randomized controlled trials. Transfusion. 2005;45:1302–7.”spa
dc.relation.references[15] “Gill JB, Rosenstein A. The use of antifibrinolytic agents in total hip arthroplasty: A meta-analysis. J Arthroplasty. 2006;21:869–73.”spa
dc.relation.references[16] “Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology. 2006;105:1034–46.”spa
dc.relation.references[17] “Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. Thromb Res. 2009;123: 687–96.”spa
dc.relation.references[18] “Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: A meta-analysis. J Bone Joint Surg Am. 2012;94:1153–9.”spa
dc.relation.references[19] J. T. Moskal and S. G. Capps, “Intra-articular Tranexamic Acid in Primary Total Knee Arthroplasty: Meta-analysis,” J. Knee Surg., vol. 31, no. 1, pp. 56–67, 2018.spa
dc.relation.references[20] M. Lacko, R. Cellar, D. Schreierova, and G. Vasko, “Comparison of intravenous and intra-articular tranexamic acid in reducing blood loss in primary total knee replacement,” Eklem Hast. ve Cerrahisi, vol. 28, no. 2, pp. 64–71, 2017.spa
dc.relation.references[21] Z. Wang and W. J. Wang, “Meta-analysis of posterolateral fusion versus 360° circumferential fusion in lumbar spondylolisthesis,” Chinese J. Tissue Eng. Res., vol. 18, no. 53, pp. 8685–8692, 2014.spa
dc.relation.references[22] S. Meena, F. Benazzo, S. Dwivedi, and M. Ghiara, “Topical versus intravenous tranexamic acid in total knee arthroplasty: A meta-analysis of randomized controlled trials,” J. Orthop. Surg., vol. 25, no. 1, pp. 1–8, 2017.spa
dc.relation.references[23] J. Poeran et al., “Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: Retrospective analysis of effectiveness and safety,” BMJ, vol. 349, no. August, pp. 1–10, 2014.spa
dc.relation.references[24] J. A. Boyle and M. M. Soric, “Impact of Tranexamic Acid in Total Knee and Total Hip Replacement,” J. Pharm. Pract., vol. 30, no. 1, pp. 89–93, 2017.spa
dc.relation.references[25] T. W. Tai, C. J. Lin, I. M. Jou, C. W. Chang, K. A. Lai, and C. Y. Yang, “Tourniquet use in total knee arthroplasty: A meta-analysis,” Knee Surgery, Sport. Traumatol. Arthrosc., vol. 19, no. 7, pp. 1121–1130, 2011.spa
dc.relation.references[26] A. A. Meta-analysis, “JSTOR Problem of Post-Modernity.pdf,” pp. 1153–1159, 2012.spa
dc.relation.references[27] D. Cankaya and C. J. Della Valle, “Blood Loss and Transfusion Rates in the Revision of Unicompartmental Knee Arthroplasty to Total Knee Arthroplasty Are Similar to Those of Primary Total Knee Arthroplasty But Are Lower Compared With the Revision Total Knee Arthroplasty,” J. Arthroplasty, vol. 31, no. 1, pp. 339–341, 2016.spa
dc.subject.proposalácido tranexámicospa
dc.subject.proposaltransfusión sanguíneaspa
dc.subject.proposalReemplazo total primario de rodillaspa
dc.publisher.grantorUniversidad Militar Nueva Granadaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1f*
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.identifier.instnameinstname:Universidad Militar Nueva Granadaspa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Militar Nueva Granadaspa
dc.identifier.repourlrepourl:https://repository.unimilitar.edu.cospa
dc.rights.localAcceso abiertospa
dc.coverage.sedeMedicinaspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/